Jan. 26, 2024 – CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, presented the latest results from its independent exter...
Oct 05, 2023 – A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups are advancing an array of tests to detect diseases sooner and personalize treatm...
CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer (CRC) screening blood test, that also detects pre-cancerous polyps, or adenomas, today announced the appointment of D...
Apr 06, 2023 – Molecular diagnostics company CellMax Life has appointed Stan Lapidus and Ron Andrews to its...
Feb 21, 2023 – Renowned industry experts support the company as it prepares for premarket approval studies...
Feb 21, 2023 – Renowned industry experts support the company as it prepares for premarket approval studies...
Feb 10, 2023 – Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer....
Jan 26, 2023 – CellMax Life announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer and advanced adenom...
NEW YORK; Jan 19, 2023 – Cancer screening firm CellMax Life shared new data this week from a multi-site prospective study of its blood-based colorectal cancer detection assay, FirstSight....
SUNNYVALE, CA; January 18, 2023 – CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced positive results from a multisite U.S. ...
FDANews; August 30, 2021 – Molecular diagnostics company CellMax Life’s FirstSight pre-cancer and cancer detection blood test has received the FDA’s Breakthrough Device designation....
GenomeWeb; August 27, 2021 – CellMax Life said this week that its FirstSight colorectal precancer and cancer detection blood test has received Breakthrough Device Designation from the US Food an...
Aug. 26, 2021 – The FirstSight blood test is a liquid biopsy, which will help measure colorectal neoplasia associated epithelial cells and DNA markers in human blood...
Aug. 25, 2021 – CellMax Life, a molecular diagnostics company, announced today that its FirstSight™ pre-cancer and cancer detection blood test has received Breakthrough Device Designation from t...
Mar 23, 2021 – CellMax Life closes Series C financing to accelerate development and regulatory approvals of FirstSight...
January 26, 2021 – A blood test for early detection of colorectal adenomas and cancer shows promise for improving survival and prevention of colorectal cancer (CRC) by enabling the stratificatio...
January 15, 2021 – A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results pr...
MedScape | June 01, 2020 A blood test detected 11 of 11 cases of colorectal cancer in a study involving 354 patients, and also spotted a majority of cases — 40 out of 53 — in which participants had ad...
Data now available, via 2020 ASCO Virtual Scientific Program, demonstrates early detection of colorectal neoplasia and significant association with size and number of polyps...
OncLive | May 08, 2020 The multimodal FirstSightCRC blood test demonstrated higher sensitivity and specificity than standard screening protocols in detecting advanced adenomas and colorectal cancer (C...
